Trials / Recruiting
RecruitingNCT07246564
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rozanolixizumab | Subcutaneous infusion |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2027-10-15
- Completion
- 2027-10-15
- First posted
- 2025-11-24
- Last updated
- 2026-03-27
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07246564. Inclusion in this directory is not an endorsement.